Grant: Alliance Grants
University of Ottawa
$270,000.00
The COVID-19 post-apocalyptic laboratory
EF 2022-23
Résumé
The current COVID-19 pandemic has exposed Canada's glaring inability to effectively supply its population with essential compounds for medical applications. Canada's incapacity to prepare a SARS-CoV-2 vaccine and anti-bacterials to treat the resultant lung superinfections, have left all Canadians vulnerable and our economy languishing. According to Drug Shortages Canada, there 15 critical shortages or discontinuations of essential medications in Canada; this is unacceptable for a G8 nation and threatens our security. Conventional synthesis of drug molecules uses technologies that are vast in scale employing large batch reactors that require tens to hundreds of millions of dollars in capital investments. Further, the failure of an advanced-stage synthetic batch for a critical drug can cause an operating loss of hundreds of thousands to millions of dollars. It is hard for Canadian business to build a case to take on such risks given the comparatively small market in Canada. An alternative strategy is to synthesize these precious compounds in flow reactors where smaller amounts of material are made at any single point in time, but continuously over longer periods of time and/or in parallel. This dramatically reduces capital investment, while making processes more manageable, safer, and eliminating costly batch failures. COVID-19 turned the spotlight on worker safety and dramatically altered the way that chemical companies operate by forcing them into shiftwork and other strategies to lower the density of workers on site. Flow chemistry technology, coupled with artificial intelligence (AI) and internet of things (IoT) will enable reactions to be set up, monitored, and tweaked remotely using robotically-fed custom-designed flow reactors being developed by the Team. These results will shared widely across Canadian industry and nuclear-medicine departments in hospitals through the involvement of Worker Safety and Prevention Services (WSPS), which will dramatically improve worker safety and would have the additional benefit of offering primary care-caregivers of children, the elderly and the seriously ill an opportunity to work in these rewarding areas by being able to conduct their work remotely.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
570902-2021
Name nom
Organ, Michael MG
Department département
Chemistry
Organization id
28
Institution établissement
University of Ottawa
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2022
Competition year année de concours
2021
Award amount
270000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1202
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Physical sciences
Area of application fr
Sciences physiques
Research subject code
3704
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Synthetic methodology
Research subject fr
Méthodologie en synthèse
Installment
inst:1
Partie
1
Nb partie
1
Application title
The COVID-19 post-apocalyptic laboratory
Application summary
The current COVID-19 pandemic has exposed Canada's glaring inability to effectively supply its population with essential compounds for medical applications. Canada's incapacity to prepare a SARS-CoV-2 vaccine and anti-bacterials to treat the resultant lung superinfections, have left all Canadians vulnerable and our economy languishing. According to Drug Shortages Canada, there 15 critical shortages or discontinuations of essential medications in Canada; this is unacceptable for a G8 nation and threatens our security. Conventional synthesis of drug molecules uses technologies that are vast in scale employing large batch reactors that require tens to hundreds of millions of dollars in capital investments. Further, the failure of an advanced-stage synthetic batch for a critical drug can cause an operating loss of hundreds of thousands to millions of dollars. It is hard for Canadian business to build a case to take on such risks given the comparatively small market in Canada. An alternative strategy is to synthesize these precious compounds in flow reactors where smaller amounts of material are made at any single point in time, but continuously over longer periods of time and/or in parallel. This dramatically reduces capital investment, while making processes more manageable, safer, and eliminating costly batch failures. COVID-19 turned the spotlight on worker safety and dramatically altered the way that chemical companies operate by forcing them into shiftwork and other strategies to lower the density of workers on site. Flow chemistry technology, coupled with artificial intelligence (AI) and internet of things (IoT) will enable reactions to be set up, monitored, and tweaked remotely using robotically-fed custom-designed flow reactors being developed by the Team. These results will shared widely across Canadian industry and nuclear-medicine departments in hospitals through the involvement of Worker Safety and Prevention Services (WSPS), which will dramatically improve worker safety and would have the additional benefit of offering primary care-caregivers of children, the elderly and the seriously ill an opportunity to work in these rewarding areas by being able to conduct their work remotely.